- |||||||||| alomfilimab (SAR445256) / Sanofi
Trial termination, Combination therapy, Metastases: Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov) - Oct 16, 2024
P1/2, N=222, Terminated,
Active, not recruiting --> Terminated; Early discontinuation based on strategic sponsor decision not driven by any safety concerns.
- |||||||||| alomfilimab (SAR445256) / Sanofi
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov) - Apr 28, 2024
P1/2, N=280, Active, not recruiting,
Active, not recruiting --> Terminated; Early discontinuation based on strategic sponsor decision not driven by any safety concerns. Trial completion date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024
- |||||||||| alomfilimab (SAR445256) / Sanofi
Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases: Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov) - Oct 11, 2023
P1/2, N=280, Active, not recruiting,
Trial completion date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024 Trial completion date: Nov 2024 --> Apr 2024 | Trial primary completion date: Nov 2024 --> Apr 2024
- |||||||||| alomfilimab (SAR445256) / Sanofi
Enrollment closed, Combination therapy, IO biomarker, Metastases: Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov) - Aug 21, 2023
P1/2, N=280, Active, not recruiting,
Trial completion date: Nov 2024 --> Apr 2024 | Trial primary completion date: Nov 2024 --> Apr 2024 Recruiting --> Active, not recruiting
- |||||||||| alomfilimab (SAR445256) / Sanofi
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases: Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer (clinicaltrials.gov) - Sep 15, 2022
P1/2, N=280, Recruiting,
Recruiting --> Active, not recruiting N=412 --> 280 | Trial completion date: May 2023 --> Nov 2024 | Trial primary completion date: May 2023 --> Nov 2024
- |||||||||| KY1044 / Kymab
A novel antibody targeting ICOS increases intratumoural cytotoxic to regulatory T cell ratio and induces tumour regression () - Oct 4, 2019 - Abstract #CRICIMTEATIAACR2019CRI-CIMT-EATI-AACR_36;
Altogether, KY1044 improved the intratumoral TEFF:TReg ratio and increased activation of TEFF cells, resulting in monotherapy efficacy or in synergistic combinatorial efficacy when administrated with the immune checkpoint blocker anti-PD-L1. In summary, our data demonstrate that targeting ICOS with KY1044 can favourably alter the intratumoral immune contexture, promoting an anti-tumour response.
|
